Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Pulmonary arterial hypertension Pipeline Drugs Market Report Overview
Pulmonary arterial hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.
Key Targets in the Pulmonary Arterial Hypertension Pipeline Market
The key targets in the pulmonary arterial hypertension pipeline market are Prostacyclin Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Soluble Guanylate Cyclase. Prostacyclin Receptor has the highest pipeline products in the pulmonary arterial hypertension pipeline market.
Pulmonary Arterial Hypertension Pipeline Market, by Targets
For more target insights, download a free report sample
Key Types of MoA in the Pulmonary Arterial Hypertension Pipeline Market
The key types of MoA in the pulmonary arterial hypertension pipeline market are Prostacyclin Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Endothelin 1 Receptor Antagonist, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Platelet Derived Growth Factor Receptor Inhibitor, Soluble Guanylate Cyclase Activator, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor. Prostacyclin Receptor Agonist has the highest pipeline products.
Pulmonary Arterial Hypertension Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key Types of RoA in the Pulmonary Arterial Hypertension Pipeline Market
The key types of RoA in the pulmonary arterial hypertension pipeline market are oral, inhalational, intravenous, subcutaneous, topical, intramuscular, and parenteral. Oral has the highest share in the pulmonary arterial hypertension pipeline market.
Pulmonary Arterial Hypertension Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Pulmonary Arterial Hypertension Pipeline Market
The key molecule types in the pulmonary arterial hypertension pipeline market are small molecule, fusion protein, monoclonal antibody, oligonucleotide, recombinant protein, gene-modified cell therapy, synthetic peptide, and aptamer. Small molecule has the highest share in the pulmonary arterial hypertension pipeline market.
For more molecule type insights, download a free report sample
Key Companies in the Pulmonary Arterial Hypertension Pipeline Market
The key companies in the Pulmonary Arterial Hypertension pipeline market are United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, and Antlia Bioscience Inc. United Therapeutics Corp has the highest share in the Pulmonary Arterial Hypertension pipeline market.
To know more about companies, download a free report sample
Market report overview
Key Targets | Prostacyclin Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Soluble Guanylate Cyclase |
Key Types of MoA | Prostacyclin Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Endothelin 1 Receptor Antagonist, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Platelet Derived Growth Factor Receptor Inhibitor, Soluble Guanylate Cyclase Activator, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor |
Key Types of RoA | Oral, Inhalational, Intravenous, Subcutaneous, Topical, Intramuscular, and Parenteral |
Key Molecule Types | Small Molecule, Fusion Protein, Monoclonal Antibody, Oligonucleotide, Recombinant Protein, Gene-Modified Cell Therapy, Synthetic Peptide, and Aptamer |
Key Companies | United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, and Antlia Bioscience Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Abivax SA
Acceleron Pharma Inc
Advent Therapeutics Inc
Aeon Respire Inc
Aerami Therapeutics Inc
Aerogen Pharma Corp
Aerovate Therapeutics Inc
AI Therapeutics Inc
Algorithm Sciences Inc
Altavant Sciences Inc
Alterras Therapeutics GmbH
Alveolus Bio Inc
Antlia Bioscience Inc
Apaxen
APEIRON Biologics AG
Apollo Therapeutics LLC
APT Therapeutics Inc
Aqualung Therapeutics Corp
Arovella Therapeutics Ltd
AstraZeneca Plc
ATXA Therapeutics Ltd
Bayer AG
Bial - Portela & Ca SA
Biogen Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
C4X Discovery Holdings Plc
Camurus AB
Capricor Therapeutics Inc
Cardiorentis AG
Celon Pharma SA
Celsion Corp
Celtaxsys Inc
Centessa Pharmaceuticals Plc
Cereno Scientific AB
Chengdu Dikang Pharmaceuticals Co Ltd
Chiesi Farmaceutici SpA
Claritas Pharmaceuticals Inc
Corsair Pharma Inc
Denovo Biopharma LLC
Eli Lilly and Co
Excubio Pharmaceuticals Inc
Galectin Therapeutics Inc
GenThera Inc
GEXVal Inc
Gilead Sciences Inc
Gmax Biopharm LLC
Gossamer Bio Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Insmed Inc
Interprotein Corp
INVENT Pharmaceuticals Inc
Johnson & Johnson
Keros Therapeutics Inc
Les Laboratoires Servier SAS
Liquidia Technologies Inc
LTT Bio-Pharma Co Ltd
Martin Pharmaceuticals Inc
Merck & Co Inc
Morphic Therapeutic Inc
Nadian Bio Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Northern Therapeutics Inc
Novartis AG
Pharmosa Biopharm Inc
Proteo Inc
PulmoSIM Therapeutics
Q BioMed Inc
Radikal Therapeutics Inc
Recursion Pharmaceuticals Inc
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Ribomic Inc
Shijiazhuang Sagacity New Drug Development Co Ltd
ShouTi Inc
SteadyMed Therapeutics Inc
Sulfateq BV
Systimmune Inc
Tenax Therapeutics Inc
Topadur Pharma AG
Translate Bio Inc
Triastek Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
Vascular BioSciences
Vasculonics LLC
VasThera Co Ltd
Vicore Pharma AB
Vivus LLC
Voronoi Group
Zymedi
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Pulmonary Arterial Hypertension pipeline market?
The key targets in the Pulmonary Arterial Hypertension pipeline market are Prostacyclin Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Soluble Guanylate Cyclase.
-
What are the key types of MoA in the Pulmonary Arterial Hypertension pipeline market?
The key types of MoA in the Pulmonary Arterial Hypertension pipeline market are Prostacyclin Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Endothelin 1 Receptor Antagonist, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Platelet Derived Growth Factor Receptor Inhibitor, Soluble Guanylate Cyclase Activator, and 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor.
-
What are the key types of RoA in the Pulmonary Arterial Hypertension pipeline market?
The key types of RoA in the Pulmonary Arterial Hypertension pipeline market are oral, inhalational, intravenous, subcutaneous, topical, intramuscular, and parenteral.
-
What are the key molecule types in the Pulmonary Arterial Hypertension pipeline market?
The key molecule types in the Pulmonary Arterial Hypertension pipeline market are small molecule, fusion protein, monoclonal antibody, oligonucleotide, recombinant protein, gene-modified cell therapy, synthetic peptide, and aptamer.
-
What are the key companies in the Pulmonary Arterial Hypertension pipeline market?
The key companies in the Pulmonary Arterial Hypertension pipeline market are United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, and Antlia Bioscience Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.